Alliance to Develop Pulmonary Therapy Device

An alliance to develop and manufacture a novel inhalation device for pulmonary therapy has been announced by Bespak (London, UK) and Battelle Pulmonary Therapeutics, Inc. (BPT, Cary, NC, USA). BPT develops pulmonary delivery devices, drugs, formulations, and inhaled cancer therapies for the treatment of respiratory and systemic diseases. Bespak is a multinational company focused on the development and manufacture of drug delivery devices and technologies.

The electrohydrodynamic (EHD) aerosol delivery technology of BPT will be used to develop high-performance devices that can be used to deliver both topically and systemically active drug compounds to the lung with greater than 90% efficiency and without the need for liquid propellants or other pressurized systems. Under the terms of the agreement, Bespak will handle the development and industrialization of the program from its facilities in North Carolina (USA).

"Our combined expertise and resources will allow us to develop a device that may be the next standard for pulmonary therapies,” said William C. Zimlich, vice president of device product development for BPT.



Related Links:
Bespak
BPT